Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S Kim, Corey Lipchik, Patrick G Gavin, Greg Yothers, Carmen J Allegra, Nicholas J Petrelli, Jennifer Marie Suga, Judith O Hopkins, Naoyuki G Saito, Terry Evans, Srinivas Jujjavarapu, Norman Wolmark, Peter C Lucas, Soonmyung Paik, Min Sun, Katherine L Pogue-Geile, Xinghua Lu
PURPOSE: A combination of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is the standard for adjuvant therapy of resected early-stage colon cancer (CC). Oxaliplatin leads to lasting and disabling neurotoxicity. Reserving the regimen for patients who benefit from oxaliplatin would maximize efficacy and minimize unnecessary adverse side effects. METHODS: We trained a new machine learning model, referred to as the colon oxaliplatin signature (COLOXIS) model, for predicting response to oxaliplatin-containing regimens...
February 5, 2024: Journal of Clinical Oncology